Patrycja Bełdzińska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patrycja Bełdzińska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aliaksandra Yurchak
Laboratory of Biophysics, Intercollegiate Faculty of Biotechnology UG and MUG, University of Gdańsk, 80-307 Gdańsk, Poland
1 shared publication - Dariusz Wyrzykowski
Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland
1 shared publication - Grzegorz Gołuński
Laboratory of Biophysics, Intercollegiate Faculty of Biotechnology UG and MUG, University of Gdańsk, 80-307 Gdańsk, Poland
1 shared publication - Jacek Piosik
Laboratory of Biophysics, University of Gdańsk, Gdańsk, Poland
1 shared publication - Karolina Gackowska
Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology UG and MUG, University of Gdańsk, 80-307 Gdańsk, Poland
1 shared publication - Katarzyna Bury
Laboratory of Molecular Biology, Intercollegiate Faculty of Biotechnology UG and MUG, University of Gdańsk, 80-307 Gdańsk, Poland
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1274
Platinum Nanoparticles as Modulators of Idarubicin Activity: A Physicochemical and In Vitro Biological Study
Background/Objectives: Cancer remains one of the leading causes of death worldwide. Although chemotherapy is widely used, it is associated with severe side effects, including myelosuppression and systemic toxicity. Nanoparticles have emerged as promising candidates for modulating drug activity. In this study, we investigated whether platinum nanoparticles (PtNPs) of various sizes interact with idarubicin (IDA), an anthracycline anticancer drug used primarily to treat acute leukaemia. Methods: Interactions between PtNPs and IDA were analysed using dynamic light scattering (DLS), atomic force microscopy (AFM), fluorescence spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and near-infrared (NIR) spectroscopy. Thermodynamic and thermal properties were assessed using isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC). Biological effects were evaluated using the Ames mutagenicity assay on the Salmonella enterica serovar Typhimurium TA98 strain and cytotoxicity assays on SK-BR-3 and MCF-7 cell lines. Results: DLS demonstrated changes in the hydrodynamic diameter of PtNPs following IDA addition, which were further supported by AFM imaging. PtNPs significantly quenched IDA fluorescence, indicating close molecular interactions, which were further supported by FTIR and NIR. ITC revealed that the interactions were endothermic, with enthalpy values ranging from 1.2 to 3.6 kcal/mol, and DSC demonstrated that the PtNP-IDA combination altered the melting temperature of IDA. Biological assays revealed that all examined PtNP sizes influenced IDA mutagenicity in the Salmonella enterica serovar Typhimurium TA98 strain. Furthermore, PtNPs modulated the cytotoxicity of IDA in SK-BR-3 and MCF-7 cell lines in a dose-dependent manner. Conclusions: These findings demonstrate that PtNPs interact with IDA and modulate its biological activity. However, in this study no non-cancerous cell lines were examined; therefore, the observed interactions and biological effects support further investigation of the PtNP-IDA combination in the context of nanoparticle-assisted anticancer therapy on a broader range of in vitro cell lines.
- 12 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1274
Open AccessPlatinum Nanoparticles as Modulators of Idarubicin Activity: A Physicochemical and In Vitro Biological Study
Background/Objectives: Cancer remains one of the leading causes of death worldwide. Although chemotherapy is widely used, it is associated with severe side effects, including myelosuppression and systemic toxicity. Nanoparticles have emerged as promising candidates for modulating drug activity. In this study, we investigated whether platinum nanoparticles (PtNPs) of various sizes interact with idarubicin (IDA), an anthracycline anticancer drug used primarily to treat acute leukaemia. Methods: Interactions between PtNPs and IDA were analysed using dynamic light scattering (DLS), atomic force microscopy (AFM), fluorescence spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and near-infrared (NIR) spectroscopy. Thermodynamic and thermal properties were assessed using isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC). Biological effects were evaluated using the Ames mutagenicity assay on the Salmonella enterica serovar Typhimurium TA98 strain and cytotoxicity assays on SK-BR-3 and MCF-7 cell lines. Results: DLS demonstrated changes in the hydrodynamic diameter of PtNPs following IDA addition, which were further supported by AFM imaging. PtNPs significantly quenched IDA fluorescence, indicating close molecular interactions, which were further supported by FTIR and NIR. ITC revealed that the interactions were endothermic, with enthalpy values ranging from 1.2 to 3.6 kcal/mol, and DSC demonstrated that the PtNP-IDA combination altered the melting temperature of IDA. Biological assays revealed that all examined PtNP sizes influenced IDA mutagenicity in the Salmonella enterica serovar Typhimurium TA98 strain. Furthermore, PtNPs modulated the cytotoxicity of IDA in SK-BR-3 and MCF-7 cell lines in a dose-dependent manner. Conclusions: These findings demonstrate that PtNPs interact with IDA and modulate its biological activity. However, in this study no non-cancerous cell lines were examined; therefore, the observed interactions and biological effects support further investigation of the PtNP-IDA combination in the context of nanoparticle-assisted anticancer therapy on a broader range of in vitro cell lines.